These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 18591752)

  • 1. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
    Ohta H
    Nihon Rinsho; 2009 May; 67(5):960-6. PubMed ID: 19432117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
    Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
    Kastelan D; Giljevic Z; Kraljevic I; Korsic M
    Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
    Ohnaka K; Takayanagi R
    Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SERMs: an update for clinicians].
    Ohta H
    Clin Calcium; 2005 Apr; 15(4):637-42. PubMed ID: 15802777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Raloxifene (Celvista, Evista)].
    Body JJ; Sternon J
    Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene for the treatment and prevention of breast cancer?
    Pappas SG; Jordan VC
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
    Burckhardt P
    Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of osteoporosis due to ovarian failure.
    Eastell R
    Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].
    Urano T
    Clin Calcium; 2005 Apr; 15(4):591-5. PubMed ID: 15802770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing and treating osteoporosis: strategies at the millennium.
    Sherman S
    Ann N Y Acad Sci; 2001 Dec; 949():188-97. PubMed ID: 11795353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoporosis management.
    Rozenberg S; Vandromme J; Ayata NB; Filippidis M; Kroll M
    Int J Fertil Womens Med; 1999; 44(5):241-9. PubMed ID: 10569453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.